Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Two Drugs Show Promise Against Severe Constipation

Help chronic cases, terminally ill patients on opiod painkillers

By Ed Edelson
HealthDay Reporter


Related Encyclopedia
 border=
Abdominoplasty
Acidophilus
Adhesions
Amebiasis
More...

Related Healthscout Videos
 border=
Nutrition and Cancer
Nutrition and Osteoporosis
Importance of Good Nutrition
Critical Nutrition
More...

Related Animations
 border=
GERD
PPI Therapy
More...

Related Drug Information
 border=
Aciphex
Nexium
Prevacid
Prilosec
More...

Related News Articles
 border=
Intestinal 'Sleeve' Mimics Effects of Gastric Bypass
Toxic Chemical Linked to Obesity
Some Diabetics at Higher Risk for Heart Disease
Exercise Eases Depression and Heart Disease
More...

WEDNESDAY, May 28 (HealthDay News) -- Two new medications offer hope for the most severe forms of constipation.

Almost 15 percent of Americans are constipated at any given time, said Dr. Michael Camilleri, lead author of one of two reports in the May 29 issue of the New England Journal of Medicine. His paper reported on the efficacy of the experimental drug prucalopride on 620 people with chronic constipation.

Text Continues Below



"A minority of people have constipation because the nerves are not working well," Camilleri said. "These people, on average, had one bowel movement every two weeks."

It's not known how many Americans have such severe constipation, but "patients with this condition are seen regularly," said Camilleri, a gastroenterologist who is professor of medicine and physiology at the Mayo Clinic, in Rochester, Minn.

In the study, 47.3 percent of the people who took 2 milligrams a day of prucalopride for 12 weeks had three or more bowel movements a week, compared to 25.8 percent of those given a placebo. The success rate for people given 4 milligrams a day of prucalopride was slightly lower, at 46.6 percent.

"The results were better than with similar medications available in the past," Camilleri said.

An accompanying editorial by Dr. Arthur J. Moss, a professor of medicine and physiology at the University of Rochester in New York, raised two questions about the drug and the trial.

Two drugs that act in the same way as prucalopride were taken off the market, because they caused heart problems, Moss said. There was no indication of such problems in the newly reported trial, but that was true of the other medications at the same point in their development, he said.

"The pre-marketing studies were benign," Moss said. "But you just don't know until you get mass marketing."

The only similarity between prucalopride and the older drugs was that they acted on a cell receptor that stimulates cells in the wall of the intestines to induce muscle contraction, Camilleri said. "There is no chemical resemblance," he said. "Those other two medications also affect a certain kind of channel in the heart conduction system which makes it likely they will be associated with abnormalities in the heart."

Page:  1 | 2 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 5/28/2008

Related Links
 border=
From Healthscout's partner site on acid reflux, AcidRefluxConnection.com
SYMPTOMS: Learn about the symptoms of acid reflux disease
DRUGS: Common medications used to treat heartburn
TREATMENT: Lifestyle changes, medication, and surgeryoptions





SOURCES: Michael Camilleri, M.D., professor, medicine and physiology, May Clinic, Rochester, Minn.; Arthur J. Moss, M.D., professor, medicine and physiology, University of Rochester, New York; May 29, 2008, New England Journal of Medicine


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service